Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Nephrology · Autosomal Dominant Tubulointerstitial Kidney Disease, SEC61A1-related

ADTKD-SEC61A1 (Autosomal Dominant Tubulointerstitial Kidney Disease, SEC61A1-related): A Patient Guide

At a Glance

ADTKD-SEC61A1 is a rare inherited kidney disease caused by a SEC61A1 gene change. It can gradually reduce kidney function and affect blood counts and growth, so lifelong monitoring and supportive care are important; transplantation can treat kidney failure without recurrence in the new kidney.

ADTKD-SEC61A1 is an ultra-rare genetic condition that affects how the kidneys and other systems in the body function over time. Formerly known as ADTKD-6, this condition is part of a group of disorders called Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD). This guide is primarily written for families of children, but ADTKD-SEC61A1 can present at any age, and the information applies to adult patients as well. Because it is so rare—with only a small number of published cases (around 15 to 20 as of recent reviews) described in the medical literature—the journey to a diagnosis often involves searching for answers to a complex puzzle of symptoms [1]. Finding the specific genetic cause in the SEC61A1 gene provides a crucial roadmap, allowing your medical team to move from uncertainty toward a targeted plan for monitoring and support [2].

At its core, this condition involves a genetic change in the instructions for a cellular structure called the translocon. Experimental studies suggest this structure acts like a doorway involved in moving proteins, such as renin, and balancing calcium within the cell’s factory [3]. When this doorway is altered, it can lead to a gradual decline in kidney function. This decline is often characterized by a “bland” urine profile, meaning there is little to no protein or blood lost in the urine early on [1]. Because the SEC61A1 gene is active throughout the body, the condition is systemic and may also involve low red blood cell counts (anemia), low white blood cell counts (neutropenia), and challenges with physical growth [4].

Managing ADTKD-SEC61A1 is a process of lifelong, proactive partnership with specialists. While there is currently no specific cure that repairs the genetic mutation, supportive care helps manage complications and protect health [5]. This includes vigilant monitoring of blood counts to quickly treat potential infections, managing blood pressure and electrolyte balance, and supporting healthy development. The pace of the disease varies, and your medical team will tailor their approach to your unique needs at every stage [2].

Looking toward the future, if the kidneys eventually reach a point where they can no longer function, kidney transplantation is a well-established solution [6]. One of the most reassuring aspects is that the genetic kidney disease does not recur in a transplanted kidney [7]. However, transplantation involves major surgery, lifelong immunosuppression, and continued monitoring, as extra-renal issues like anemia or neutropenia may persist. While the rarity of this diagnosis can feel isolating, it also places your family at the forefront of medical understanding, supported by a clear path for proactive, long-term care.

Common questions in this guide

What is ADTKD-SEC61A1 and what causes it?
ADTKD-SEC61A1 is an ultra-rare inherited condition caused by a change in the SEC61A1 gene. It gradually affects kidney function and can also affect blood counts and physical growth. The diagnosis gives the care team information for long-term monitoring and support.
What kidney and whole-body changes can ADTKD-SEC61A1 cause?
Kidney function may decline gradually, and early urine tests may show little or no protein or blood. Some people develop anemia, neutropenia, which means a low level of infection-fighting white blood cells, or growth problems. The pattern and speed can vary from person to person.
How is ADTKD-SEC61A1 managed over time?
There is no treatment that currently repairs the SEC61A1 gene change. Care focuses on regular kidney and blood-count checks, blood pressure and electrolyte management, prompt attention to infections, and support for healthy development. The monitoring plan is adjusted to each person’s needs.
Will ADTKD-SEC61A1 come back after a kidney transplant?
If kidney function eventually fails, a kidney transplant is an established treatment option. The genetic kidney disease does not recur in the transplanted kidney, but transplant surgery and lifelong medicines to prevent rejection are required. Anemia or neutropenia may continue, so other medical monitoring remains important.
Which specialists may be part of care for ADTKD-SEC61A1?
A nephrologist can coordinate kidney care, while a hematology specialist can help monitor anemia and neutropenia. A medical genetics professional can explain the SEC61A1 result and discuss testing for relatives. Other specialists may be added based on growth, infections, or transplant needs.
Should family members be tested for the SEC61A1 gene change?
Relatives may be able to have genetic testing to determine whether they carry the same SEC61A1 change. A medical genetics team can explain who should be tested, what the results mean, and how testing may affect care. Testing decisions should be made with the family’s healthcare team.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on tubulointerstitial kidney disease, autosomal dominant 6.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the rarity of this condition, how can we ensure our care is coordinated between the kidney team and other specialists like hematology?
  2. 2.What specific signs of 'bland' kidney disease should we be monitoring in routine blood and urine tests?
  3. 3.How does the knowledge of the SEC61A1 mutation change the way we monitor growth and the immune system compared to other kidney patients?
  4. 4.If we eventually need to consider transplantation, what is the process for testing family members to ensure they don't carry the same mutation?

References

References (7)
  1. 1

    De novo SEC61A1 mutation in congenital anemia and early-onset kidney disease: Case report and review of the literature.

    Zhong L, Ding J, Ma M, et al.

    Gene 2026; (993()):150106 doi:10.1016/j.gene.2026.150106.

    PMID: 41850665
  2. 2

    Hypoaldosteronism due to a novel SEC61A1 variant successfully treated with fludrocortisone.

    Karpman D, Lindström ML, Möller M, et al.

    Clinical kidney journal 2024; (17(8)):sfae213 doi:10.1093/ckj/sfae213.

    PMID: 39135939
  3. 3

    Phenylbutyrate rescues the transport defect of the Sec61α mutations V67G and T185A for renin.

    Sicking M, Živná M, Bhadra P, et al.

    Life science alliance 2022; (5(4)) doi:10.26508/lsa.202101150.

    PMID: 35064074
  4. 4

    Heterozygous Loss-of-Function SEC61A1 Mutations Cause Autosomal-Dominant Tubulo-Interstitial and Glomerulocystic Kidney Disease with Anemia.

    Bolar NA, Golzio C, Živná M, et al.

    American journal of human genetics 2016; (99(1)):174-87.

    PMID: 27392076
  5. 5

    Optimal patient care in advanced chronic kidney disease progressing to kidney failure.

    Combe C, Alencar de Pinho N, Guedes M, et al.

    Nature reviews. Nephrology 2026; (22(6)):406-421 doi:10.1038/s41581-026-01056-2.

    PMID: 41667648
  6. 6

    Renal transplant outcomes in patients with autosomal dominant tubulointerstitial kidney disease.

    Cormican S, Kennedy C, Connaughton DM, et al.

    Clinical transplantation 2020; (34(2)):e13783 doi:10.1111/ctr.13783.

    PMID: 31958169
  7. 7

    Diagnosis and Long-term Management of Uromodulin Kidney Disease.

    Wheeler E, Thomas S

    Cureus 2019; (11(3)):e4270 doi:10.7759/cureus.4270.

    PMID: 31157132

This page is for informational purposes only and does not constitute medical advice about ADTKD-SEC61A1. Your nephrologist, genetics specialist, and other clinicians should interpret genetic results and plan monitoring for your family.